Literature DB >> 15897534

Meta-analysis: accuracy of rapid tests for malaria in travelers returning from endemic areas.

Arthur Marx1, Daniel Pewsner, Matthias Egger, Reto Nüesch, Heiner C Bucher, Blaise Genton, Christoph Hatz, Peter Jüni.   

Abstract

BACKGROUND: Microscopic diagnosis of malaria is unreliable outside specialized centers. Rapid tests have become available in recent years, but their accuracy has not been assessed systematically.
PURPOSE: To determine the accuracy of rapid diagnostic tests for ruling out malaria in nonimmune travelers returning from malaria-endemic areas. DATA SOURCES: The authors searched MEDLINE, EMBASE, CAB Health, and CINAHL (1988 to September 2004); hand-searched conference proceedings; checked reference lists; and contacted experts and manufacturers. STUDY SELECTION: Diagnostic accuracy studies in nonimmune individuals with suspected malaria were included if they compared rapid tests with expert microscopic examination or polymerase chain reaction tests. DATA EXTRACTION: Data on study and patient characteristics and results were extracted in duplicate. The main outcome was the likelihood ratio for a negative test result (negative likelihood ratio) for Plasmodium falciparum malaria. Likelihood ratios were combined by using random-effects meta-analysis, stratified by the antigen targeted (histidine-rich protein-2 [HRP-2] or parasite lactate dehydrogenase [LDH]) and by test generation. Nomograms of post-test probabilities were constructed. DATA SYNTHESIS: The authors included 21 studies and 5747 individuals. For P. falciparum, HRP-2-based tests were more accurate than parasite LDH-based tests: Negative likelihood ratios were 0.08 and 0.13, respectively (P = 0.019 for difference). Three-band HRP-2 tests had similar negative likelihood ratios but higher positive likelihood ratios compared with 2-band tests (34.7 vs. 98.5; P = 0.003). For P. vivax, negative likelihood ratios tended to be closer to 1.0 for HRP-2-based tests than for parasite LDH-based tests (0.24 vs. 0.13; P = 0.22), but analyses were based on a few heterogeneous studies. Negative likelihood ratios for the diagnosis of P. malariae or P. ovale were close to 1.0 for both types of tests. In febrile travelers returning from sub-Saharan Africa, the typical probability of P. falciparum malaria is estimated at 1.1% (95% CI, 0.6% to 1.9%) after a negative 3-band HRP-2 test result and 97% (CI, 92% to 99%) after a positive test result. LIMITATIONS: Few studies evaluated 3-band HRP-2 tests. The evidence is also limited for species other than P. falciparum because of the few available studies and their more heterogeneous results. Further studies are needed to determine whether the use of rapid diagnostic tests improves outcomes in returning travelers with suspected malaria.
CONCLUSIONS: Rapid malaria tests may be a useful diagnostic adjunct to microscopy in centers without major expertise in tropical medicine. Initial decisions on treatment initiation and choice of antimalarial drugs can be based on travel history and post-test probabilities after rapid testing. Expert microscopy is still required for species identification and confirmation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15897534     DOI: 10.7326/0003-4819-142-10-200505170-00009

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  59 in total

1.  Parasitic infections, anemia and malnutrition among rural settled and mobile pastoralist mothers and their children in Chad.

Authors:  M Bechir; E Schelling; M A Hamit; M Tanner; J Zinsstag
Journal:  Ecohealth       Date:  2011-12-13       Impact factor: 3.184

2.  Shifting from presumptive to test-based management of malaria - technical basis and implications for malaria control in Ghana.

Authors:  F Baiden; K Malm; C Bart-Plange; A Hodgson; D Chandramohan; J Webster; S Owusu-Agyei
Journal:  Ghana Med J       Date:  2014-06

3.  Malaria diagnosis by NOW ICT and expert microscopy in comparison with multiplex polymerase chain reaction in febrile returned travellers.

Authors:  J Cuadros; P Martín-Rabadán; F J Merino; A Delgado-Irribarren; S Garcia-Bujalance; J M Rubio
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-09       Impact factor: 3.267

Review 4.  [Malaria].

Authors:  G Burchard
Journal:  Internist (Berl)       Date:  2006-08       Impact factor: 0.743

Review 5.  Imported Malaria in Countries where Malaria Is Not Endemic: a Comparison of Semi-immune and Nonimmune Travelers.

Authors:  Johannes Mischlinger; Caroline Rönnberg; Míriam J Álvarez-Martínez; Silja Bühler; Małgorzata Paul; Patricia Schlagenhauf; Eskild Petersen; Michael Ramharter
Journal:  Clin Microbiol Rev       Date:  2020-03-11       Impact factor: 26.132

6.  Combined deletions of pfhrp2 and pfhrp3 genes result in Plasmodium falciparum malaria false-negative rapid diagnostic test.

Authors:  Sandrine Houzé; Véronique Hubert; Gaëlle Le Pessec; Jacques Le Bras; Jérôme Clain
Journal:  J Clin Microbiol       Date:  2011-05-04       Impact factor: 5.948

Review 7.  Update on rapid diagnostic testing for malaria.

Authors:  Clinton K Murray; Robert A Gasser; Alan J Magill; R Scott Miller
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

8.  Test characteristics of the SD FK80 Plasmodium falciparum/Plasmodium vivax malaria rapid diagnostic test in a non-endemic setting.

Authors:  Philippe Gillet; David P J van Dijk; Emmanuel Bottieau; Lieselotte Cnops; Marjan Van Esbroeck; Jan Jacobs
Journal:  Malar J       Date:  2009-11-22       Impact factor: 2.979

9.  Evaluation of the SD FK70 malaria Ag Plasmodium vivax rapid diagnostic test in a non-endemic setting.

Authors:  Philippe Gillet; Katrien Bosselaers; Lieselotte Cnops; Emmanuel Bottieau; Marjan Van Esbroeck; Jan Jacobs
Journal:  Malar J       Date:  2009-06-11       Impact factor: 2.979

10.  Assessment of the prozone effect in malaria rapid diagnostic tests.

Authors:  Philippe Gillet; Marcella Mori; Marjan Van Esbroeck; Jef Van den Ende; Jan Jacobs
Journal:  Malar J       Date:  2009-11-30       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.